Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study. CLARIFY
Description:
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor:
Clarity PharmaceuticalsContacts:
Clarity Pharmaceuticalsclinicaltrials@claritypharmaceuticals.com
+61 (0) 2 9209 4037
Government Study Link:
NCT06056830 - Click here to see study onClinicalTrials.gov
64Cu-SAR-bisPSMA
- PSMA
- • Patients electing to undergo RP with PLND.
- • Untreated, histologically confirmed adenocarcinoma of the prostate
- • High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines Version 1.2023
- •Patients with known predominant small cell or neuroendocrine PC
- •Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedure
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
United States 🇺🇸
17607 Gold Plaza, Omaha, Nebraska 68130, United States
Myrtle Beach, South Carolina, United States
Madison, Wisconsin 53792, United States
Principal Investigator
Steve Y Cho, MD
Tulsa, Oklahoma 74146, United States
Principal Investigator
Shaun GS Grewal, MD
Stanford, California 94305, United States
Principal Investigator
Hong Song, MD, Ph.D.
Los Angeles, California, United States
Principal Investigator
Gholam Berenji, MD
Dallas, Texas, United States
Principal Investigator
Alexander Parker, MD
Utah, United States
Principal Investigator
Dustin L. Boothe, MD
Rochester, Minnesota, United States
Principal Investigator
Jeffrey Karnes, MD
Nashville, Tennessee, United States
Principal Investigator
David Morris, MD
Michigan, United States
Principal Investigator
Brian R. Lane MD
San Antonio, Texas, United States
Principal Investigator
Naveen Kella, MD
Phoenix, Arizona, United States
Principal Investigator
Jack Andrews, MD
Jacksonville, Florida, United States
Principal Investigator
Ephraim Parent, MD, PhD
Grand Rapids, Michigan 49503, United States
Principal Investigator
Harshad Kulkarni, M.D.
Dallas, Texas 75390, United States
Principal Investigator
Orhan K. Oz, MD, PhD
Glenview, Illinois 60026, United States
Principal Investigator
Brian Helfand, MD
Indianapolis, Indiana, United States
Australia 🇦🇺
Sydney, New South Wales, Australia
Woolloongabba, Queensland, Australia
Principal Investigator
Professor Ian Vela, MBBS, PhD
